Litigation

Helsinn Healthcare S.A. v. Dr. Reddy's Laboratories, Ltd.

related/consolidated

3:12-cv-02867

Filed
2012-05-11

Patents at issue (2)

8598219
7947724

Summary

Companion 505(b)(2)/NDA case in the Helsinn Aloxi palonosetron litigation, predominantly concerning the '724 chelating agent issue. Consolidated/related to the lead D.N.J. action.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

I'll research this case thoroughly before drafting.

Good foundation. Now let me verify the docket specifics, the 2017 decision, and appeal history.

Now let me retrieve the docket and confirm appeal outcomes and the '219 patent's role.

Case Overview — Helsinn Healthcare S.A. v. [Dr. Reddy's Laboratories, Ltd.](/litigations/by-plaintiff/Dr.%20Reddy's%20Laboratories%2C%20Ltd.), No. 3:12-cv-02867 (D.N.J.)

The parties. Helsinn Healthcare S.A. is a privately held, family-controlled Swiss pharmaceutical company based in Lugano that develops and licenses supportive-care oncology drugs; it is an operating innovator, not an NPE or university. Helsinn does not itself commercialize Aloxi® in the United States — U.S. marketing rights are held by Eisai Inc. (which books U.S. sales) and the product is co-promoted by Eisai and Helsinn Therapeutics (U.S.) Inc. Helsinn's co-plaintiff, Roche Palo Alto LLC (a Delaware entity at One DNA Way, South San Francisco), is the successor to Syntex and the licensor of the underlying palonosetron compound patent; Helsinn took an exclusive license in 1998 and the two entities together hold the formulation patents. The defendants are Dr. Reddy's Laboratories, Ltd. (Hyderabad, India) and its wholly owned U.S. subsidiary Dr. Reddy's Laboratories, Inc. (Bridgewater, New Jersey) — a large multinational generic-drug manufacturer. Both DRL entities had previously consented to personal jurisdiction in the District of New Jersey in the earlier Helsinn actions, which is why the case landed there. (See Compl. ¶¶ 1–4; Helsinn v. Teva, 855 F.3d 1356, 1360–61 (Fed. Cir. 2017).)

The accused product and the patents. Unlike the lead Aloxi case (No. 11-3962), which targeted ANDAs, this action arises from DRL's "paper NDA" under 21 U.S.C. § 355(b)(2) — NDA No. 203050 — for palonosetron hydrochloride 0.25 mg/5 mL (0.05 mg/mL) intravenous solution referencing Helsinn's NDA No. 021372 for Aloxi®. That regulatory route is the crux of the case: a 505(b)(2) filer can rely on the pioneer's safety and efficacy data while altering excipients, and DRL's formulation substituted sodium acetate trihydrate for the EDTA required by the claims. The two patents listed in the case metadata are U.S. Patent No. 7,947,724 (issued May 24, 2011, "Liquid Pharmaceutical Formulations of Palonosetron") — claims a shelf-stable aqueous palonosetron formulation at 0.05 mg/mL with a chelating agent (EDTA) and 18/24-month room-temperature stability — and U.S. Patent No. 8,598,219 (issued Dec. 3, 2013) — claims a single-use 0.25 mg/5 mL dose with EDTA and mannitol, stable for 24 months at room temperature. Both descend from provisional application No. 60/444,351. *(Accuracy caveat: public sources do not show the '219 being pleaded against DRL's 505(b)(2) NDA in 12-2867. The patents actually litigated to judgment in this case were the '724, plus 8,729,094 and 9,066,980, which were added via No. 14-4274 and consolidated here; the '219 was asserted against DRL in the companion ANDA action, No. 11-3962, where DRL was dismissed by stipulation on Oct. 16, 2015. The metadata appears to reflect the '219's role in the coordinated Aloxi litigation rather than this docket's operative pleadings.)*

Procedural posture and why it matters. Filed May 11, 2012 and assigned to Judge Mary L. Cooper (with Magistrate Judge Douglas E. Arpert) in the Trenton vicinage — the same judge who presided over the entire Aloxi case family, which matters because it produced one coordinated claim construction across the ANDA and 505(b)(2) tracks. On January 17, 2013, Judge Cooper stayed the case pending the validity determination of the '724 in No. 11-3962 (Dkt. 37). The court construed "a chelating agent" as "a multidentate ligand that can form a ring structure by reacting with a metal ion" (Apr. 2, 2015, Dkts. 91–92); after a six-day bench trial (June 20–28, 2016), the court held on February 14, 2017 that DRL's product infringes claim 9 of the '724 and claims 27 and 6 of the '094 and '980, and that the asserted '094/'980 claims were not invalid for lack of written description or enablement — DRL having stipulated to infringement of the other ten claims (2017 U.S. Dist. LEXIS 21477; Dkt. 232). The case is notable on three fronts: (1) the "chelating agent" ruling swept in sodium acetate — an excipient not conventionally treated as a chelator — effectively closing the 505(b)(2) design-around and reinforcing Aloxi's exclusivity, which with pediatric exclusivity ran to July 30, 2024; (2) it is the companion to the far more consequential Helsinn v. Teva, 855 F.3d 1356 (Fed. Cir. 2017), aff'd, 586 U.S. 731 (2019), which held the AIA's on-sale bar reaches secret sales — a ruling that arose from No. 11-3962, not this docket, and that reshaped the validity landscape for the same patent family; and

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

I'll research this case across the docket, opinions, PTAB, and Federal Circuit records.

Let me dig into the 12-2867 docket specifically and the Feb 2017 DRL decision.

Now let me check the post-trial disposition in 12-2867, any appeal, and the PTAB proceedings.

In the news

What the press has reported about this case, summarized with links to the source articles.

I'll research press coverage of this litigation across multiple search angles.

I have some initial hits. Let me dig into specific outlets and the key rulings.

Now let me look for coverage of the 2017 ruling in trade press, and the subsequent settlement/launch news.

What the press reported

The only substantial press coverage of this docket clusters around Judge Cooper's February 14, 2017 post‑trial ruling in D.N.J. C.A. No. 12‑2867, the 505(b)(2) "paper NDA" case against Dr. Reddy's. Law360 summarized it on 2017‑02‑15 as a win for Helsinn: a New Jersey federal judge "found that Dr. Reddy's Laboratories Inc.'s planned generic version of Helsinn Healthcare SA's anti-nausea drug Aloxi infringes three patents for the drug and rejected Dr. Reddy's contention that two of those patents are invalid." Life Sciences IP Review ("Dr Reddy's found to infringe chemo drug patents") identified the patents as U.S. 7,947,724, 8,729,094 and 9,066,980 and quoted the court's holding that "[w]e find that the asserted claims in the '724, '094, and '980 patents are infringed… [and] are not invalid for lack of written description [or] lack of enablement," noting that Helsinn asserted 13 claims and that Dr. Reddy's conceded it would infringe ten of them if valid. Robins Kaplan's Generically Speaking bulletin framed the outcome as driven "in large part" by the earlier Markman construction, and Lexology's case note of 2017‑02‑21 is the most technically detailed account, explaining that the sole infringement dispute was whether the sodium acetate trihydrate in Dr. Reddy's product was a "chelating agent" as construed ("a multidentate ligand that can form a ring structure by reacting with a metal ion"), and that the court refused to let Dr. Reddy's re-litigate that term at the infringement step. That chelating-agent issue is the "724 issue" the case is known for.

On resolution, the primary-source press is corporate rather than journalistic. Helsinn's own release of 2015‑10‑13 announced a settlement with Dr. Reddy's permitting a 505(j) generic launch "on September 30, 2018, or earlier under certain circumstances," with the remaining terms confidential. Livemint covered the same announcement, adding the only market-size figure I found in press: Aloxi sales of "nearly $416 million in the U.S. and Canada for the year ended 31 March." Eisai, Helsinn's U.S. marketing partner, issued a 2015‑11‑17 release confirming the Dr. Reddy's and Sandoz settlements and stating that the formulation patents plus pediatric exclusivity covered Aloxi "through to July 30, 2024, subject to any appeal." Neither outlet reported any damages figure, and none appears to have been at issue: the relief sought in these § 271(e)(2) actions is a date-shifting order and injunction, not money damages.

Reporting diverges from the docket in a few places, and commentary frequently goes beyond this case. Livemint's account is notably imprecise — it dates the complaint to 2013 and says "an injunction was issued, preventing the generic manufacturers from launching," which conflates the 2011 action, the Sandoz consent judgment, and later events; the Helsinn release and the court record describe a negotiated launch date rather than a litigated injunction against Dr. Reddy's in this docket. Lexology is also where the widest framing appears, tallying the Aloxi litigation at "19 separate civil actions" in D.N.J., D. Del. and E.D. Pa., with Helsinn having settled against fifteen generics and "eight actions against six generics still pending" as of early 2017

Sources

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

I'll research the docket and appearances for this case.

Counsel of Record for Plaintiff Helsinn Healthcare S.A. — D.N.J. No. 3:12-cv-02867 (MLC)(DEA)

Sourcing caveat up front. The 12-2867 docket itself is not freely mirrored in full (CourtListener/Plainsite coverage of this docket is patchy, and many substantive filings were sealed), so I could not pull a live PACER attorney report. However, the roster below is grounded in signed, public filings in this action and in the consolidated lead case, which share an identical caption block: the original complaint (Dkt. 1, filed May 11, 2012), the joint claim construction papers (Dkt. 174, filed May 23, 2014, in the consolidated 11-3962/13-5815 docket), Judge Cooper's Markman order (Dkt. 91, Feb. 19, 2015), and the Rule 11.2/40.1 related-case certifications naming 12-2867. I flag below the two attorneys whose 12-2867 appearance I could not independently confirm.

Core team: Paul Hastings LLP (New York) — national/lead counsel

Attorney Role Firm / office Note
Joseph M. O'Malley, Jr. Lead counsel (first-listed; argued the case) Paul Hastings LLP, 75 E. 55th St., New York, NY (later 200 Park Ave.) Dean of the Helsinn palonosetron team across every D.N.J. action; led the Helsinn appeal in Helsinn v. Teva, Nos. 2016-1284/-1787 (Fed. Cir.) and the certiorari petition that produced Helsinn Healthcare S.A. v. Teva, 586 U.S. 731 (2019) — signature block on the Feb. 2018 cert petition lists O'Malley, Dittmann, Park and Ashkenazi.
Bruce M. Wexler Of counsel / partner Paul Hastings LLP, New York Listed on the complaint's "Of Counsel" block; registered patent attorney and long-time Hatch-Waxman/formulation litigator.
Eric W. Dittmann Of counsel / partner; principal day-to-day courtroom lawyer Paul Hastings LLP, New York Appeared for plaintiffs at the Sept. 7, 2012 proceedings in the consolidated litigation and on the Fed. Cir./SCOTUS Helsinn briefs.
David M. Conca Of counsel Paul Hastings LLP, New York Listed on the complaint and on the 2014 claim construction submissions.
Gary Ji Of counsel / associate Paul Hastings LLP, New York Listed in every Helsinn 12-2867 signature block through the appellate petition.
Angela C. Ni Associate Paul Hastings LLP, New York Member of the NY and NJ bars and admitted to the D.N.J.; executed the claim-construction declaration in the consolidated action, describing herself as "an associate at … Paul Hastings LLP … counsel for Plaintiff Helsinn Healthcare S.A."

Attorneys who appear for Helsinn in the sister Aloxi cases but whose 12-2867 notices of appearance I could not verify: Young J. Park, Isaac S. Ashkenazi, Dana Weir (Paul Hastings — appeared in the Actavis, Sagent and 2016–17 actions and on the appellate/cert papers).

Local counsel: Saul Ewing LLP (Newark, NJ)

Attorney Role Firm / office Note
Charles M. Lizza Local counsel (D.N.J. signatory on all filings) Saul Ewing LLP (now Saul Ewing Arnstein & Lehr LLP), One Riverfront Plaza, Suite 1520, Newark, NJ 07102 The firm's Hatch-Waxman anchor in New Jersey; he signed the L. Civ. R. 11.2/40.1 certifications tying 12-2867 to 11-3962, 11-5579, 13-5815 and 14-4274, and remained Helsinn's NJ counsel through the Supreme Court phase.
William C. Baton Local counsel Saul Ewing LLP, Newark, NJ Co-signatory with Lizza on the complaint and every subsequent 12-2867 filing.

Note the unusual posture: the caption block consistently reads Lizza/Baton "Attorneys for Plaintiffs Helsinn Healthcare S.A. and Roche Palo Alto LLC," while the Paul Hastings block is styled "Attorneys for Plaintiff Helsinn Healthcare S.A." only.

Counsel for original co-plaintiff Roche Palo Alto LLC

Attorney Role Firm / office Note
Mark E. Waddell Outside counsel to co-plaintiff Roche Palo Alto LLC Loeb & Loeb LLP, 345 Park Ave., New York, NY 10154 Roche, as co-assignee of the '724/'725/'424/'219 patents, appeared through Loeb & Loeb; Roche was later dismissed from the Aloxi litigation by stipulation, after which Helsinn litigated 12-2867 alone (the Feb. 14, 2017 trial opinion, 2017 U.S. Dist. LEXIS 21477, names Helsinn as the sole plaintiff).

What I could not confirm

  • No in-house Helsinn attorney appears on any public signature block or notice of appearance in 12-2867; Helsinn's legal department (Swiss/Lugano-based) did not enter an appearance.
  • Sarah Ann Sullivan filed a notice of appearance "on behalf of HELSINN HEALTHCARE S.A., ROCHE PALO ALTO LLC" in the related Sagent action (3:16-cv-00681) and is likely Saul Ewing local counsel, but I found no 12-2867 notice of appearance for her and have not listed her as counsel here.
  • Several 12-2867 filings (expert reports, damages contentions, the 2016 trial record) were filed under seal; sealed materials may contain additional appearances not reflected above.
  • I did not verify current firm affiliations as of today — the firms/offices listed reflect the period of the litigation (2012–2019).

Key citations

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

I'll research the counsel of record for Dr. Reddy's Laboratories in this Helsinn palonosetron case.

Key names are surfacing. Let me pin down the actual docket for 3:12-cv-02867 and the defendant's appearances.

Let me pull the actual signature blocks and the 12-2867 docket details.

Counsel of Record — Dr. Reddy's Defendants (Dr. Reddy's Labs., Ltd. & Dr. Reddy's Labs., Inc.)

Bottom line: In this 505(b)(2) "paper NDA" action (No. 12-2867), DRL's counsel of record was Lerner David Littenberg Krumholz & Mentlik LLP of Westfield, New Jersey, with William L. Mentlik and Michael H. Teschner as the lead attorneys. In the consolidated/related lead ANDA action (No. 11-3962), DRL was represented by Budd Larner, P.C. of Short Hills, New Jersey, led by Stuart D. Sender. Both firms are New Jersey-based; the Helsinn litigation was unusual in that DRL's lead patent counsel were also its local counsel.

Lerner David Littenberg Krumholz & Mentlik LLP — 600 South Avenue West, Westfield, NJ 07090

Name Role Note
William L. Mentlik Lead counsel of record (12-2867); named signatory on DRL's notice of appeal Registered patent attorney and Lerner David name partner; signed DRL's March 7, 2017 Notice of Appeal from Judge Cooper's Feb. 14, 2017 judgment (Dkt. 232) and final judgment (Dkt. 239); lead petitioner counsel for DRL in IPR2015-01550/-01553/-01554 and PGR2016-00007 against Helsinn's palonosetron patents.
Michael H. Teschner Lead trial counsel / principal DRL contact attorney USPTO Reg. No. 32,862. Identified in PTAB testimony as the attorney through whom the DRL engagement originated ("The original contact was with an attorney, Michael Teschner…"); signed DRL's IPR petitions and served as PGR petitioner counsel.
Roy H. Wepner Of counsel / appellate signatory Lerner David name partner and long-time Hatch-Waxman litigator; listed on DRL's Notice of Appeal in this action.
Russell W. Faegenburg Of counsel Listed on DRL's Notice of Appeal; corresponded on PTAB exhibit service in the DRL/Helsinn proceedings.
Stephen F. Roth Of counsel Listed on DRL's Notice of Appeal in this action.
Tedd W. Van Buskirk Of counsel Listed on DRL's Notice of Appeal in this action.
Maegan A. Fuller Associate / of counsel Listed both on the Notice of Appeal and as DRL's IPR/PGR counsel of record (service address in IPR2015-01554).
Thomas M. Palisi Associate / of counsel DRL IPR counsel of record (IPR2015-01554 service list).
Nichole M. Valeyko Associate Served as DRL's PTAB counsel of record alongside Mentlik and Teschner in the 2016 PGR.

Budd Larner, P.C. — 150 J.F. Kennedy Parkway, Short Hills, NJ 07078 (counsel in the consolidated lead ANDA action, No. 11-3962)

Name Role Note
Stuart D. Sender Lead / local counsel for DRL Signed DRL's filings in the consolidated Helsinn actions (11-3962); long-time DRL outside Hatch-Waxman counsel in D.N.J. and in multiple Federal Circuit appeals.
Michael H. Imbacuan Of counsel Named on DRL's consolidated-action signature blocks.
H. Howard Wang Of counsel Same.
Stephanie L. Donahue Of counsel Same.

In-house

  • Lee Banks, Esq. — Dr. Reddy's Laboratories, Inc., 200 Somerset Corporate Blvd., Floor 7, Bridgewater, NJ 08807. He was not counsel of record; he was the in-house attorney designated in DRL's March 30, 2012 notice letter as DRL's authorized agent for service of process in New Jersey (recited in Helsinn's complaint, No. 12-2867).

Important caveats and sourcing notes

  1. "Of record" vs. appearance history. I could not query PACER directly (paywalled); I relied on RECAP/CourtListener, Justia's D.N.J. opinions, PTAB filings, and firm websites. I therefore cannot give you the specific docket numbers of each attorney's notice of appearance. The roster above is drawn from operative filed signature blocks — principally DRL's Notice of Appeal (Mar. 7, 2017) in No. 12-2867, which lists the Lerner David team as "Attorneys for Defendants Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc." — not from appearance entries themselves.

  2. Firm shift between the two actions. DRL's counsel in No. 11-3962 was Budd Larner (Sender et al.); DRL's counsel in the 505(b)(2) action No. 12-2867 was Lerner David. This is confirmed by the signature blocks in each case's filings and by the PTAB service certificates, which list the Lerner David attorneys as "counsel of record for Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc." Because No. 12-2867 was stayed and administratively terminated in January 2013 (Dkt. 37, Jan. 17, 2013 opinion), reopened, and then consolidated with No. 14-4274 for the '094/'980 issues, the exact point at which Lerner David supplanted or supplemented Budd Larner is not something I could verify from a docket sheet.

  3. Do not attribute the Hill Wallack / Morrison & Foerster blocks to DRL. One frequently-cited consolidated filing (ECF No. 174 in No. 11-3962) contains signature blocks for Eric I. Abraham and Christy L. Saveriano (Hill Wallack LLP, Princeton) and David C. Doyle, E. Cary Miller, Matthew M. D'Amore, Jayson L. Cohen, and Hui Liu (Morrison & Foerster, San Diego/New York) alongside Budd Larner's. Based on the Jan. 17, 2014 deposition transcript in the same litigation, which identifies "MORRISON FORRESTER LLP — Attorneys for Defendant Sandoz Inc.," those blocks belong to co-defendant Sandoz, not DRL. Treat any source that lists MoFo as DRL's counsel in this litigation as an error.

  4. No sealed-counsel issue identified. Nothing in the record I reviewed suggests DRL proceeded anonymously or that its counsel was sealed; the sealing in this litigation (e.g., Dkt. 91, the Feb. 19, 2015 Markman order, originally under seal) concerned substantive filings, not appearances.

  5. Post-judgment posture, flagged as uncertain. Judge Cooper entered judgment for Helsinn on Feb. 14, 2017 (Dkt. 232) and final judgment Mar. 6, 2017 (Dkt. 239); DRL noticed appeal on Mar. 7, 2017. I did not verify the Federal Circuit disposition of that appeal (the widely reported 2019 decision, Helsinn Healthcare S.A. v. Dr. Reddy's Labs. Ltd., 387 F. Supp. 3d 439 (D.N.J.), and the Supreme Court's Helsinn v. Teva, 586 U.S. 731 (2019), on the AIA on-sale bar, arose from the Teva branch of the litigation, not this DRL appeal). If you need the appellate counsel of record, that requires a separate check of the Federal Circuit docket.